Burjeel Medical City (BMC), the flagship facility of Burjeel Holdings, has partnered with UK-based innovative healthcare solutions provider, Digipharm, in order to design and validate a new model for patient care in the UAE.
The alliance intends to provide the best-advanced health technologies and create an enhanced end-to-end patient experience.
The new platform, which has the potential to revolutionize the digital healthcare ecosystem, will focus initially on the Bone Marrow Transplantation program and will later expand to other specialties at the hospital.
According to the agreement, BMC and Digipharm will work closely together to implement digitally enabled Value-based Healthcare (VBHC) and Value-based Procurement (VBP) provisions.
Mr. John Sunil CEO – Burjeel Holdings
“At Burjeel Holdings, we firmly believe that technology is a game-changer for advancing healthcare delivery. By leveraging cutting-edge technology, we aim to enhance the patient experience, improve outcomes and drive innovation in healthcare. We are excited to explore how the new technology can be used to improve Bone Marrow Transplant outcomes. Such collaborations will also bolster the UAE’s transformation journey into a global leader in healthcare.”
The partnership between BMC and Digipharm seeks to serve patients across the UAE with access to the most innovative health technologies that ensure optimized clinical pathways, and improved patient outcomes and experiences.
As per the agreement, “BMC will work with the company to lay the foundations to implement Digipharm’s ‘Reimburse’ Platform and the ‘Digihealth’ (patient-reported outcomes) Application to enable VBHC and VBP at the hospital.”
Mr. Ahmed Abdulla, CEO of Digipharm, said that “this collaboration will also allow us as a solution provider to validate our delivery models in host institutions and patient populations outside of the UK and Europe in a country that is leading digital transformation in the region.”
